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Vaccinia virus has two infectious forms, the intracellular mature virus, which has a single envelope,
and the extracellular enveloped virus (EEV), which is surrounded by two lipid bilayers. The
outer membrane of the EEV contains at least six viral proteins. Among them A34, a type II
membrane glycoprotein, and B5, a type I membrane glycoprotein, form a complex and are involved
in processes such as morphogenesis and EEV entry. A34 is required for normal incorporation
of B5 into the EEV membrane. Here, we used a virus lacking B5 and viruses with mutations in
the B5 membrane-proximal stalk region and looked at the effect of those modifications on A34.
Data presented show that B5 is required for the correct glycosylation, trafficking and stability of
A34, emphasizing the complex interactions and mutual dependence of these vaccinia EEV
proteins.
Vaccinia virus (VACV) is the prototypical member of the
genus Orthopoxvirus of the Poxviridae. It replicates in the
cytosol and produces multiple types of infectious virions
(Smith et al., 2002; Condit et al., 2006; Roberts & Smith,
2008). The first infectious progeny is the intracellular mature
virus (IMV), which is surrounded by a single-lipid envelope
(Dales & Siminovitch, 1961; Hollinshead et al., 1999) and
remains in the cell until cell lysis. However, some IMV are
transported via microtubules tothe early endosomes or trans-
Golgi network where they are wrapped by two cellular
membranes containing several VACV proteins. The resulting
intracellular enveloped virus (IEV) is then transported on
microtubules to the cell surface where the outer membrane
fuses with the plasma membrane to externalize a double-
enveloped virus by exocytosis. This virion is called cell-
associated enveloped virus (CEV) if it remains on the cell
surface, or extracellular enveloped virus (EEV) if it is released
fromthecell.TheCEV/EEVoutermembranecontainsatleast
six viral proteins: A33 (Roper et al., 1996), A34 (Duncan &
Smith, 1992), A56 (Shida, 1986), B5 (Engelstad et al., 1992;
Wolffe et al., 1993), F13 (Blasco & Moss, 1991) and K2
(Turner & Moyer, 2006; Wagenaar & Moss, 2007). A34 is a
type II transmembrane protein with different glycoforms
between 23 and28 kDa anditsextracellular part containsa C-
type lectin-like domain (Duncan & Smith, 1992). A K151D
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A34, which is present naturally in the VACV International
Health Department (IHD)-J strain, caused an increasein EEV
release (Blasco et al.,1 9 9 3 ) .S i m i l a r l y ,d e l e t i o no ft h eA34R
gene (vDA34R) from VACV WR caused a 25-fold increase in
EEV, but such EEV had a fivefold reduction in specific
infectivity (McIntosh & Smith, 1996). Deletion or suppression
of the A34R gene caused a small plaque phenotype (Duncan &
Smith, 1992; McIntosh & Smith, 1996), inability to form actin
tails (Wolffe et al., 1997; Sanderson et al., 1998) and severe
attenuation (McIntosh & Smith, 1996).
B5 is a 42 kDa type I transmembrane glycoprotein
(Engelstad et al., 1992; Isaacs et al., 1992) with an
extracellular domain composed of four short consensus
repeats (SCRs) characteristic of complement control
proteins (Takahashi-Nishimaki et al., 1991), although there
is no evidence that B5 regulates complement activity. After
the SCRs B5 has an acidic stalk region (ST) before the
transmembrane domain (TM) and a short cytoplasmic tail
(CT). Both the SCRs and CT are dispensable for targeting
B5 to the EEV membrane (Herrera et al., 1998; Lorenzo
et al., 1998; Mathew et al., 1998), although the latter affects
its transport to the cell surface (Mathew et al., 2001) and
recycling via endosomes (Ward & Moss, 2000). B5 is
needed for IMV wrapping to form IEV (Engelstad & Smith,
1993; Wolffe et al., 1993). B5 and A34 interact (Rottger
et al., 1999; Earley et al., 2008; Perdiguero et al., 2008;
Roberts et al., 2009) and in the absence of A34, the amount
of B5 incorporated in EEV is decreased markedly (Earley
et al., 2008; Perdiguero et al., 2008; Roberts et al., 2009). B5
and A34 each affect the glycosaminoglycan (GAG)-
dependent rupture of the EEV outer membrane during
EEV entry (Law et al., 2006; Roberts et al., 2009).
Although B5 expressed on its own displays a cellular
localization profile very similar to the one observed in the
context of viral infection (Katz et al., 1997; Lorenzo et al.,
2000), this is not the case for A34. In infected cells, A34 is
found at the Golgi, on the cell surface and in CEV/EEV. In
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perinuclear region and does not go to the plasma membrane
(Lorenzo et al., 2000). In addition, attempts to express A34 on
its own from classical eukaryotic expression vectors
(pcDNA3, pCI) and in several recombinant expression
systems yielded poor levels of expression. For example, in a
system where soluble forms of EEV proteins A56, B5 and A33
were expressed in CHO cells and secreted into the medium,
the yield obtained for A34 was about 20-fold lower than for
B5 (Law et al., 2005; Pu ¨tz et al., 2005; M. Law unpublished
data). Here, we present data showing that in the absence of
B5, the level of A34 is markedly decreased, most probably
because of misfolding and consequential degradation.
In a recent study on EEV entry, we generated several VACV
mutants with alterations in the B5 stalk acidic residues
(Roberts et al., 2009), for the structure of these mutants see
Fig. 1(a). Using those viruses, we analysed lysates from
infected RK13 cells by immunoblotting with mouse
monoclonal antibodies (mAbs) against B5 (36-6; Roberts
et al., 2009), A34 (34-1; Roberts et al., 2009) and the IMV
protein D8 (AB1.1; Parkinson & Smith, 1994) as an
infection control (Fig. 1b). Mouse mAbs against the A34
and B5 proteins were produced by immunization of mice
with purified recombinant protein expressed from mam-
malian cells (Law et al., 2005; Pu ¨tz et al., 2005). As noted
previously, these mutations affected the electrophoretic
mobility of B5 (Roberts et al., 2009). In addition, this
analysis showed that in the absence of B5, the amount of
A34 in the infected cells was reduced considerably, and
with some of the B5 mutants the glycosylation profile of
A34 was different. When B5 was deleted, one distinct band
at about 20 kDa (A34*) was observed instead of the 23–
28 kDa bands made by wild-type (WT) virus. In contrast,
deletion of all the B5 SCRs (vSCR0), had no effect and A34
retained the WT profile (note the remaining B5 fragment
was not visible due to its small size). However, substitution
of the acidic residues of the stalk with alanines (vST2-
35ala) had the same effect as deleting B5. Moreover,
substitution of the five acidic residues closest to the
membrane (vST23-35ala) also led to the A34* profile.
Interestingly, vST2-16 and vST28-35 showed a mixed
profile with the A34* band evident together with higher
molecular mass forms (Fig. 1b). Since vST23-35ala and
vST28-35ala differ only at residue 23 and display distinct
A34 glycosylation profiles, we wondered if that amino acid
could by itself influence A34 glycosylation. To address this,
a recombinant VACV in which the aspartic acid 23 of the
stalk region was mutated to alanine (vST23ala) was
constructed by using transient dominant selection as
described previously (Roberts et al., 2009). When tested
by immunoblotting as above, vST23ala showed the same
A34 profile as the WT virus and therefore, mutating the
aspartic acid 23 is not sufficient to alter A34 glycosylation
(Fig. 1c). Overall, analysis of these mutants suggested that
the B5 stalk is important for correct glycosylation of A34.
To determine more precisely the nature of the A34 20 kDa
isoform, we used drugs that affect glycosylation: namely
tunicamycin, an inhibitor of N-acetylglucosamine transfer-
ase and kifunensin, an inhibitor of a-mannosidase I
(Fig. 2a). RK13 cells were infected with WR or vDB5R at 5
p.f.u. per cell for 90 min and then incubated overnight in
Dulbecco’s modified Eagle’s medium containing 2.5% fetal
bovine serum with or without 1 mM tunicamycin or 5 mM
kifunensin. Cell lysates were then prepared and analysed by
immunoblotting (Fig. 2b). Treatment of WR-infected cells
with tunicamycin produced a single A34 band, correspond-
ing to the unglycosylated polypeptide (A34ug). The A34ug is
(a)
(b)
(c)
Fig. 1. B5 affects the abundance and size of A34. (a) Structure of
the B5 stalk mutants used in this study. The amino acid residues of
the stalk are numbered 1–39 and modified residues are shown in
bold. (b, c). RK13 cells were infected with the indicated viruses
and cell lysates were prepared at 16 h post-infection (p.i.) and
immunoblotted with mAbs against B5, D8 and A34. The positions
of molecular mass markers are shown on the left in kDa.
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observeda slightly smaller band of about 17 kDa. In vDB5R-
infected cells, A34 is slightly larger than A34ug and was still
reduced in size in the presence of tunicamycin, indicating
that A34* is a partially glycosylated form. Notably, levels of
B5 and A34 both decreased in the presence of tunicamycin,
indicating that glycosylation is required for stability of these
proteins. In the presence of kifunensin, the A34* pattern was
observed in WR-infected cells, suggesting that A34*
represents an intermediate with nine mannose residues
(Man9), before trimming by the a-mannosidases.
Another interesting observation was that the amount of
A34 in the absence of B5 was increased by kifunensin
treatment. This is in agreement with reports showing that
processing by a-mannosidases acts as a signal to target
misfolded proteins for proteasomal degradation and that
inhibition of these enzymes by kifunensin treatment leads to
accumulation of misfolded (Man9)-glycoproteins (Olivari
& Molinari, 2007). To address this further, the stability of
A34 with time was investigated (Fig. 2c). RK13 cells were
infected with WR or vDB5R as before and cell lysates were
prepared at 4, 8, 12 and 24 h p.i. and analysed by
immunoblotting. Up to 8 h p.i., A34 was easily detected in
cells infected by either virus, although it was less abundant
in vDB5R-infected cells, but thereafter A34 declined
substantially in vDB5R-infected cells and was barely visible
at 24 h. This suggests that synthesis and accumulation of
A34 starts normally without B5, but as the rate of synthesis
decreases later during infection, the level of A34 declines.
Collectively, those data suggest that in the absence of B5,
A34 is misfolded and degraded.
Next, the effect of A34 glycosylation status on the
subcellular localization was investigated. BSC-1 cells were
infected with viruses at 2 p.f.u. per cell for 8 h, fixed with
PBS–4% paraformaldehyde (PFA) for 10 min on ice and
then in PBS–8% PFA for 20 min at room temperature.
Fixed cells were permeabilized with 0.2% Triton X-100 and
incubated with anti-A34 mAb and a rabbit anti-protein
disulphide isomerase Ab (anti-PDI; Abcam) to stain the
endoplasmic reticulum (Fig. 3). Consistent with Fig. 2(c),
significant levels of A34 were present in both WR- and
vDB5R-infected cells at 8 h p.i. In WR-infected cells, the
anti-A34 mAb labelled the Golgi as well as punctate
structures corresponding to virions in the periphery,
as described previously (Lorenzo et al., 2000), but no
significant co-localization with PDI was observed
(Fig. 3a). In contrast, in vDB5R-infected cells A34 was
(a)
(b)
(c)
Fig. 2. In the absence of B5, A34 has aberrant glycosylation and
is targeted for degradation. (a) Simplified diagram of the
glycosylation pathway showing where tunicamycin and kifunensin
act. Gluc, Glucose; GlcNAc, N-acetylglucosamine; Man, mannose.
(b) RK13 cells were infected with WR and vDB5R and incubated
with or without tunicamycin (Tunic.) or kifunensin (Kifu.). At 16 h
p.i., cell lysates were prepared and analysed by immunoblotting
with anti-B5, anti-D8 and anti-A34 mAbs. Another image of the
bottom section of the membrane is shown for clarity. A34ug and
B5ug, unglycosylated A34 and unglycosylated B5. (c) A34 is
synthesized in the absence of B5, but is degraded over time. RK13
cells were infected with WR or vDB5R and harvested at the
indicated times p.i. Cell lysates were prepared and analysed by
immunoblotting as in (b). The positions of molecular mass markers
are shown on the left in kDa.
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localizing with PDI (Fig. 3a), similar to that seen when A34
was expressed from a Semliki Forest virus vector (Lorenzo
et al., 2000). No staining of VACV particles was observed,
and this may be explained by the wrapping defect of vDB5R
(Engelstad & Smith, 1993; Wolffe et al., 1993). Cells
infected with vDB5R, vST23-35ala and vST28-35ala all
showed a significant amount of A34 in the ER and nuclear
envelope, but vST23-35ala and vST28-35ala also showed
some staining of viral particles (Fig. 3b; enlargement of the
punctate staining representing virions is shown for the
vST28-35 image). Cells infected with vST23-35ala generally
had fewer particles than WR- or even vST28-35ala-infected
cells. This is consistent with the fact that vST23-35
produced much less EEV than WR, whereas EEV
production by vST28-35ala was only slightly reduced
(Roberts et al., 2009). Overall, these data show that the
A34* band in SDS-PAGE correlates with the presence of
A34 in the ER. This is consistent with A34* being a
(Man9)-A34 that accumulates in the ER.
Data presented here indicate that in the absence of B5, or
in presence of some mutated forms of B5, A34 is not
correctly folded and accumulates in the ER as a partially
glycosylated intermediate. Ultimately, at least in the case of
vDB5R, this would lead to proteasomal degradation. A
hypothesis to explain these data would be that an
interaction of the negatively charged acidic residues in
the B5 stalk region with positive charges of A34 might help
A34 to acquire the correct conformation. Alternatively, the
B5 stalk could play a role in the trafficking of the B5/A34
complex.
Taken together with the previous data showing that A34 is
required for proper incorporation of B5 in the EEV
membrane, this shows that there is a complex mutual
interaction between these two VACV proteins making it
difficult to unravel their respective roles in virus wrapping,
egress and re-entry due to their inter-dependence.
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